Drug intelligence / Profile preview

ropivacaine + fentanyl + adrenaline

Development stage
Unknown
Lead developer
AstraZeneca
Modality
Peptides, Small Molecules
Administration
Epidural, Intrathecal, Regional
01

Overview

This is a combination drug consisting of three active pharmaceutical ingredients: - **Ropivacaine**: an amide-type local anesthetic that blocks nerve impulse transmission by inhibiting sodium channels, providing regional anesthesia and analgesia. - **Fentanyl**: a potent synthetic opioid agonist at the mu-opioid receptor, used for its strong analgesic properties. - **Adrenaline (epinephrine)**: a sympathomimetic agent that acts primarily on alpha and beta adrenergic receptors. When added to local anesthetics in epidural or regional anesthesia, it causes vasoconstriction at the injection site, which slows systemic absorption of the anesthetic and opioid, prolongs their effect, and may reduce toxicity. This combination is commonly used in epidural infusions for postoperative pain management after major surgeries such as knee arthroplasty or abdominal surgery. The addition of adrenaline/epinephrine aims to enhance analgesia by reducing vascular uptake of both ropivacaine and fentanyl[1][4]. However, clinical studies have shown mixed results regarding whether adding adrenaline significantly improves pain relief compared to ropivacaine plus fentanyl alone[1][4].

Other names
ropivacaine + fentanyl + epinephrine
02

Targets

ADRB1 (β1)MOR (Mu opioid receptor)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)ADRA1 (Alpha-1 adrenergic receptor family)

Beyond the preview

Go deeper on ropivacaine + fentanyl + adrenaline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ropivacaine + fentanyl + adrenaline.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call